Genetic characterization of N-acetyltransferase 2 variants in acquired multidrug-resistant tuberculosis in Indonesia.
Rika YuliwulandariKinasih PrayuniIntan RazariRetno W SusilowatiYenni ZulhamidahSoedarsono SoedarsonoAbdul Salam M SofroKatsushi TokunagaPublished in: Pharmacogenomics (2021)
Background: Owing to the high resistance rate of tuberculosis (TB) to isoniazid, which is metabolized by N-acetyltransferase 2 (NAT2), we investigated the associations between NAT2 variants and multidrug-resistant (MDR)-TB. Materials & methods: The acetylator status based on NAT2 haplotypes of 128 patients with MDR-TB in Indonesia were compared with our published data from patients with anti-TB drug-induced liver injury (AT-DILI), TB and the general population. Results: NAT2*4 was more frequent in the MDR-TB group than in the AT-DILI group, TB controls and general controls. NAT2*4/*4 was significantly more frequent in patients with MDR-TB than in those with AT-DILI. NAT2*5B/7B, *6A/6A and *7B/*7B were detected at lower frequencies in patients with AT-DILI. Rapid acetylators were significantly more frequent in patients with MDR-TB than in those with AT-DILI. Conclusion: These results provide an initial data for optimizing TB treatment in the Indonesian population, and suggest that NAT2 genotyping may help to select appropriate treatment by predicting TB-treatment effect.
Keyphrases
- mycobacterium tuberculosis
- multidrug resistant
- drug induced
- drug resistant
- gram negative
- pulmonary tuberculosis
- acinetobacter baumannii
- randomized controlled trial
- gene expression
- electronic health record
- systematic review
- machine learning
- escherichia coli
- emergency department
- copy number
- artificial intelligence
- big data
- replacement therapy
- high resolution
- hepatitis c virus
- combination therapy
- deep learning
- sensitive detection
- atomic force microscopy
- antiretroviral therapy
- genetic diversity